Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20548650 | 1.00 | L3MBTL1 (0.43) | L3MBTL1NPC1GLARAB9AKMT2A | |
| SCHEMBL30314346 | 0.95 | KMT2A (0.47) | L3MBTL1NPC1GLARAB9AKMT2A | |
| SCHEMBL20548655 | 0.95 | KMT2A (0.47) | L3MBTL1NPC1GLARAB9AKMT2A | |
| SCHEMBL20548435 | 0.92 | NPC1 (0.40) | L3MBTL1NPC1GLARAB9AKMT2A | |
| SCHEMBL30314537 | 0.92 | NPC1 (0.40) | L3MBTL1NPC1GLARAB9AKMT2A | |
| SCHEMBL30314311 | 0.91 | PKM (0.45) | L3MBTL1NPC1GLARAB9AKMT2A | |
| SCHEMBL20548663 | 0.91 | PKM (0.45) | L3MBTL1NPC1GLARAB9AKMT2A | |
| SCHEMBL20548667 | 0.91 | LMNA (0.43) | L3MBTL1NPC1GLARAB9AKMT2A | |
| SCHEMBL30314516 | 0.91 | LMNA (0.43) | L3MBTL1NPC1GLARAB9AKMT2A | |
| SCHEMBL20548631 | 0.90 | LMNA (0.44) | L3MBTL1NPC1GLARAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11623919-B2 | Heterocyclic P2X7 antagonists | BREYE THERAPEUTICS APS (DK) | 2023-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11623919-B2 | Heterocyclic P2X7 antagonists | P2RY1, P2RX1, P2RX3 | L3MBTL1 4468/4885NPC1 468/4885GLA 4388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.